经皮左心耳封堵预防心房颤动卒中的研究进展

doi:10.16138/j.1673-6087.2022.05.009

摘要/Abstract

中图分类号:

R541.75

尹翔, 郑良荣. 经皮左心耳封堵预防心房颤动卒中的研究进展[J]. 内科理论与实践, 2022, 17(05): 392-395.

YIN Xiang, ZHENG Liangrong. Research progress of percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 392-395.

参考文献 29

[1]	周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志, 2004, 43(7): 491-494.
[2]	Cresti A, García-Fernández MA, Sievert H, et al. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study[J]. EuroIntervention, 2019, 15(3): e225-e230. doi: 10.4244/EIJ-D-19-00128 URL
[3]	Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE)[J]. Circulation, 2021, 144(19): 1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063 URL
[4]	Galea R, Mahmoudi K, Gräni C, et al. Watchman FLX vs. watchman 2.5 in a dual-center left atrial appendage closure cohort[J]. Europace, 2022.[Epub ahead of print].
[5]	Galea R, De Marco F, Meneveau N, et al. Amulet or Watchman device for percutaneous left atrial appendage closure[J]. Circulation, 2022, 145(10): 724-738. doi: 10.1161/CIRCULATIONAHA.121.057859 URL
[6]	Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus Warfarin therapy for prevention of stroke in patients with atrial fibrillation[J]. Lancet, 2009, 374(9689): 534-542. doi: 10.1016/S0140-6736(09)61343-X pmid: 19683639
[7]	Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure[J]. Circulation, 2011, 123(4): 417-424. doi: 10.1161/CIRCULATIONAHA.110.976449 URL
[8]	Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy[J]. J Am Coll Cardiol, 2014, 64(1): 1-12. doi: 10.1016/j.jacc.2014.04.029 pmid: 24998121
[9]	Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure[J]. J Am Coll Cardiol, 2017, 70(24): 2964-2975. doi: 10.1016/j.jacc.2017.10.021 URL
[10]	Godino C, Melillo F, Bellini B, et al. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk[J]. EuroIntervention, 2020, 15(17): 1548-1554. doi: EIJ-D-19-00507 pmid: 31845892
[11]	Nielsen-Kudsk JE, Korsholm K, Damgaard D, et al. Cli-nical outcomes associated with left atrial appendage occlu-sion versus direct oral anticoagulation in atrial fibrillation[J]. JACC Cardiovasc Interv, 2021, 14(1): 69-78. doi: 10.1016/j.jcin.2020.09.051 URL
[12]	Osmancik P, Tousek P, Herman D, et al. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)[J]. Am Heart J, 2017, 183: 108-114. doi: S0002-8703(16)30215-0 pmid: 27979034
[13]	Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol, 2020, 75(25): 3122-3135. doi: S0735-1097(20)35175-5 pmid: 32586585
[14]	Osmancik P, Herman D, Neuzil P, et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(1): 1-14.
[15]	Price MJ, Slotwiner D, Du C, et al. Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States[J]. JACC Cardiovasc Interv, 2022, 15(7): 741-750. doi: 10.1016/j.jcin.2022.02.009 URL
[16]	Boersma LV, Ince H, Kische S, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the Watchman left atrial appendage closure technology[J]. Circ Arrhythm Electrophysiol, 2019, 12(4): e006841. doi: 10.1161/CIRCEP.118.006841 URL
[17]	Aonuma K, Yamasaki H, Nakamura M, et al. Efficacy and safety of left atrial appendage closure with Watchman in Japanese nonvalvular atrial fibrillation patients[J]. Circ J, 2020, 84(8): 1237-1243. doi: 10.1253/circj.CJ-20-0196 URL
[18]	Phillips KP, Santoso T, Sanders P, et al. Left atrial appendage closure with Watchman in Asian patients[J]. Int J Cardiol Heart Vasc, 2019, 23: 100358.
[19]	Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation[J]. J Am Coll Cardiol, 2013, 61(25): 2551-2556. doi: 10.1016/j.jacc.2013.03.035 URL
[20]	Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy[J]. EuroIntervention, 2017, 12(17): 2075-2082. doi: EIJ-D-16-00726 pmid: 27973336
[21]	Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation[J]. J Am Coll Cardiol, 2018, 71(14): 1528-1536. doi: S0735-1097(18)33229-7 pmid: 29622159
[22]	Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion[J]. Europace, 2020, 22(2): 184. doi: 10.1093/europace/euz258 URL
[23]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国左心耳封堵预防心房颤动卒中专家共识(2019)[J]. 中华心血管病杂志, 2019(12): 937-938.
[24]	Enomoto Y, Gadiyaram VK, Gianni C, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device[J]. Heart Rhythm, 2017, 14(1): 19-24. doi: S1547-5271(16)30938-9 pmid: 27771552
[25]	Bergmann MW, Betts TR, Sievert H, et al. Safety and efficacy of early anticoagulation drug regimens after Watchman left atrial appendage closure[J]. EuroIntervention, 2017, 13(7): 877-884. doi: EIJ-D-17-00042 pmid: 28606886
[26]	Saw J, Nielsen-Kudsk JE, Bergmann M, et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure[J]. JACC Cardiovasc Interv, 2019, 12(11): 1067-1076. doi: 10.1016/j.jcin.2018.11.001 URL
[27]	Merkulova I, Pevzner D, Rytova Y, et al. Antithrombotic treatment after the left atrial appendage occlusion: impact on clinical outcomes in russian prospective registry[J]. J Am Coll Cardiol, 2022, 79(9): 795. doi: 10.1016/S0735-1097(22)01786-7 URL
[28]	Li X, Zhang X, Jin Q, et al. Clinical efficacy and safety comparison of rivaroxaban and dabigatran for nonvalvular atrial fibrillation patients undergoing percutaneous left atrial appendage closure operation[J]. Front Pharmacol, 2021, 12: 614762. doi: 10.3389/fphar.2021.614762 URL
[29]	Duthoit G, Silvain J, Marijon E, et al. Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure[J]. Circ Cardiovasc Interv, 2020, 13(7): e8481.

经皮左心耳封堵预防心房颤动卒中的研究进展

Research progress of percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴立群. 大道至简——肺静脉隔离新技术[J]. 内科理论与实践, 2022, 17(05): 357-359.
[2]	陆林, 代杨, 王晓群, 吴立群, 张瑞岩, 沈卫峰. 心血管转化研究的若干进展[J]. 内科理论与实践, 2022, 17(05): 369-372.
[3]	费镇涛, 陈牧, 李毅刚. 心房颤动导管消融后复发机制的研究进展[J]. 内科理论与实践, 2022, 17(05): 396-399.
[4]	张芝, 汤学超, 黄新苗, 秦永文. 脉冲电场消融在心房颤动中的应用[J]. 内科理论与实践, 2022, 17(05): 400-404.
[5]	徐敏, 张京岚. 非心脏手术后新发心房颤动患者的相关临床分析[J]. 内科理论与实践, 2022, 17(04): 334-336.
[6]	白英, 刘心遥, 张溪林, 高兆芳, 史旭波, 邓可武. 规范抗凝对心房颤动住院患者预后的影响[J]. 内科理论与实践, 2021, 16(06): 409-412.
[7]	赵英妹, 聂红明, 张珏, 黄燕. 肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(05): 480-483.
[8]	术超, 管甲亮, 李喆, 刘禹, 王学锋, 武文漫. 稀释蝰蛇毒时间试验与混合试验在狼疮抗凝物检测中的相关性研究[J]. 诊断学理论与实践, 2020, 19(1): 28-31.
[9]	刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558.
[10]	武冬冬, 胡夏生, 刘银红, 蒋景文. 脑微出血的临床意义及其伴心房颤动时的抗凝治疗决策进展[J]. 诊断学理论与实践, 2020, 19(05): 534-539.
[11]	罗晓颖, 许燕, 张建盛, 吴立群, 戚文航. N端脑钠肽前体预测首次急性心肌梗死后新发心房颤动的价值研究[J]. 诊断学理论与实践, 2020, 19(03): 303-307.
[12]	王晨琛, 杨文波, 华玮, 陈晔芬, 苏秀秀, 龚俊世, 方跃华. 左心耳解剖形态、功能与非瓣膜性心房颤动患者脑卒中发生风险的相关性研究[J]. 诊断学理论与实践, 2020, 19(02): 151-156.
[13]	康凯, 曹久妹. 利伐沙班抗凝效果评估方法的研究进展[J]. 诊断学理论与实践, 2019, 18(2): 218-222.
[14]	毛毅敏, 黄伸伸, 和雪改. 围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理[J]. 诊断学理论与实践, 2019, 18(1): 16-20.
[15]	钟伙花, 屈剑锋, 肖卫民, 陈仰昆, 丘东海, 罗根培,. 急性缺血性卒中合并肌钙蛋白I升高的相关因素和预后研究[J]. 内科理论与实践, 2019, 14(05): 289-293.